Guggenheim Maintains Buy on Relay Therapeutics, Raises Price Target to $22
Guggenheim analyst Brad Canino maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $15 to $22.
Login to comment